Baird initiated coverage of EyePoint Pharmaceuticals with an Outperform rating and $33 price target.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EYPT:
- EyePoint reports inducement grants under Nasdaq listing rule
- EyePoint completes enrollment in oversubscribed Phase 2 DAVIO 2 trial
- EyePoint Pharmaceuticals Completes Enrollment in Oversubscribed Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for Maintenance Treatment of Wet AMD
- EyePoint Pharmaceuticals Announces Upcoming Data Presentations at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
- EyePoint says it maintains a ‘de minimis’ amount of cash with SVB